What have we learnt from targeted anti-TNF therapy?

Annals of the Rheumatic Diseases

Volumn 69, Issue SUPPL. 1, 2010, Pages

  Feldmann, M ^a   Williams, R O ^a   Paleolog, E ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; TRYPTOPHAN; TUMOR NECROSIS FACTOR INHIBITOR; ANTHRANILIC ACID; CD200 FC FUSION PROTEIN; CD200 RECEPTOR; ETANERCEPT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

CELL INTERACTION; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; HUMAN; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; REACTOR CASCADE; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; TREATMENT OUTCOME; CLINICAL EFFECTIVENESS; COGNITION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DRUG EFFECT; DRUG POTENCY; DRUG TARGETING; HEALTH CARE NEED; MOLECULARLY TARGETED THERAPY; PROTEIN FUNCTION; RISK BENEFIT ANALYSIS; THERAPY EFFECT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COGNITION DISORDERS; CYTOKINES; DRUG DESIGN; HUMANS; POSTOPERATIVE COMPLICATIONS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 75749115504     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.117143     Document Type: Review

References (25)

1. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
2. Brennan FM, Chantry D, Jackson A, et al. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;2:244-7.
3. Haworth C, Brennan FM, Chantry D, et al. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factoralpha. Eur J Immunol 1991;21:2575-9.
4. Butler DM, Maini RN, Feldmann M, et al. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti-TNFα antibody with the IL-1 receptor antagonist. Eur Cytokine Network 1995;6:225-30.
5. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Nat Acad Sci USA 1992;89:9784-8.
6. Feldmann M, Maini RN. Anti-TNFα therapy or rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001;19:163-96.
7. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
8. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
9. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:855.
10. Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999;163:1521-8.
11. Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007;66:1162-7.
12. Taylor PC, Peters AM, Paleolog E, et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum 2000;43:38-47.
13. van Vollenhoven RF, Klareskog L. Clinical responses to tumor necrosis factor alpha antagonists do not show a bimodal distribution: data from the Stockholm tumor necrosis factor alpha followup registry. Arthritis Rheum 2003;48:1500-3.
14. Lipsky PE, van der Heijde DMFM, St Clair W, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
15. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
16. Aletaha D, Funovits J, Breedveld FC, et al. Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. Arthritis Rheum 2009;60:1242-9.
17. Genovese MC. Inhibition of p38: has the fat lady sung? Arthritis Rheum 2009;60:317-20.
18. Miotla J, Maciewicz R, Kendrew J, et al. Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab Invest 2000;80:1195-205.
19. Sumariwalla PF, Cao Y, Wu H-L, et al. The angiogenesis inhibitor protease-activated kringles 1-5 reduces the severity of murine collagen-induced arthritis. Arthritis Res Therapy 2003;5:R32-9.
20. Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004;50:1412-9.
21. Weinblatt M, Schiff M, Goldman A, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis 2007;66:228-34.
22. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004;4:762-74.
23. Platten M, Ho PP, Youssef S, et al. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 2005;310:850-5.
24. Inglis JJ, Criado G, Andrews M, et al. The anti-allergic drug, N-(3′,4′-dimethoxycinnamonyl) anthranilic acid, exhibits potent anti-inflammatory and analgesic properties in arthritis. Rheumatology (Oxford) 2007;46:1428-32.
25. Simelyte E, Criado G, Essex D, et al. CD200-Fc, a novel antiarthritic biologic agent that targets proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis. Arthritis Rheum 2008;58:1038-43.